Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy.

doi:10.3390/ijms27167356

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy.

International journal of molecular sciences - 17 Aug 2026

Seipel Katja, Gonçalves Fonseca Marta, Shaforostova Inna, Lee Seok-Yun, Bacher Ulrike, Pabst Thomas

Abstract excerpt

Chimeric antigen receptor CAR T-cells are effective immunotherapies for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) with overall response rates of 63-84% and complete response rates of 43-54%. Programmed cell death protein 1 (PD-1) is a cell surface receptor with immune check-point function. There are several common germline variants of the PDCD1 gene, including the linked...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Germ-Line Mutation
Share to Immunotherapy, Adoptive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Large B-Cell, Diffuse

Share to Polymorphism, Single Nucleotide

Share to Programmed Cell Death 1 Receptor

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42653360
DOI: 10.3390/ijms27167356
PMCID: PMC13513131

Genes

PDCD1
CD19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.